<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02780609</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18630</org_study_id>
    <nct_id>NCT02780609</nct_id>
  </id_info>
  <brief_title>Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma</brief_title>
  <official_title>Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I: The primary purpose of this study phase is to determine the best dose also referred&#xD;
      to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose&#xD;
      melphalan as a conditioning regimen for hematopoietic cell transplant.&#xD;
&#xD;
      Phase II: The primary purpose of this study phase is to assess the complete response (CR)&#xD;
      conversion rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Recommended Phase II Dose (RPh2D)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>RPh2D/Maximum Tolerated Dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. MTD: the highest dose level at which 1 or less of 6 participants experience a dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Complete Response (CR)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>Complete response (CR) conversion rate. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.&#xD;
tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.&#xD;
Complete Response conversion rate. CR: Negative immunofixation of serum and urine, disappearance of any soft tissue plasmacytomas, and ≤ 5% plasma cells in bone marrow.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>Progressive Disease (PD) as outlined by International Myeloma Working Group (IMWG) uniform response criteria by response subcategory for multiple myeloma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>Rate of participants' survival at time of evaluation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of Minimal Residual Disease (MRD)</measure>
    <time_frame>3 months post HCT</time_frame>
    <description>To assess minimal residual disease (MRD) with PET scan, bone marrow flow cytometry and/or immunoglobulin gene sequencing at 3 months after autologous HCT (exploratory endpoint).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 100 mg/m^2 IV over 30-45 minutes.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Cell Transplantation (HCT)</intervention_name>
    <description>Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant</intervention_name>
    <description>Fosaprepitant at 150 mg IV on days -3 and -2.</description>
    <arm_group_label>Selinexor Plus HDM HCT</arm_group_label>
    <other_name>antiemetic agent</other_name>
    <other_name>Standare of Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older with histologically confirmed multiple myeloma&#xD;
&#xD;
          -  Achieving partial response (PR) or very good partial response (VGPR) with systemic&#xD;
             chemotherapy&#xD;
&#xD;
          -  Received less than 4 lines of anti-myeloma therapy.&#xD;
&#xD;
          -  Karnofsky performance status of &gt;= 70%&#xD;
&#xD;
          -  Adequate pulmonary, cardiac, hepatic and renal function as outlined in the protocol&#xD;
&#xD;
          -  Signed informed consent form in accordance with institutional policies prior to the&#xD;
             initiation of high-dose therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-secretory multiple myeloma&#xD;
&#xD;
          -  Have achieved complete response (CR) prior to autologous hematopoietic cell&#xD;
             transplantation (HCT)&#xD;
&#xD;
          -  Central nervous system (CNS) involvement&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or fungal infections&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart&#xD;
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe&#xD;
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities.&#xD;
&#xD;
          -  Prior malignancies within the last 5 years except resected basal cell carcinoma or&#xD;
             treated cervical carcinoma in situ.&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  Have received other investigational drugs within 14 days prior to screening&#xD;
&#xD;
          -  Prior autologous or allogeneic HCT&#xD;
&#xD;
          -  Prior organ transplant or autoimmune disease requiring immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiga Nishihori, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous hematopoietic cell transplantation (HCT)</keyword>
  <keyword>high-dose melphalan</keyword>
  <keyword>selinexor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

